NumFin

PolyPeptide Group AG

符号: PPGN.SW

SIX

30.85

CHF

今天的市场价格

  • -20.2164

    市盈率

  • -0.4777

    PEG比率

  • 1.02B

    MRK市值

  • 0.00%

    DIV收益率

PolyPeptide Group AG (PPGN-SW) 财务报表

Download
年度季度
线性对数
在图表中，您可以看到 的动态默认数字 PolyPeptide Group AG (PPGN.SW). 的默认数据。公司收入显示 248.327 M 的平均值，即 0.105 % 增长率。整个期间的平均毛利润为 60.536 M，即 -0.142 %. 平均毛利率为 0.263 %. 公司去年的净收入增长率为 -7.623 %，等于 -1.275 % % 整个公司历史的平均增长率.,

年度季度
10Y20Y30Y40Y

资产负债表

深入分析 PolyPeptide Group AG 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为 ，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.197. 在流动资产领域，PPGN.SW 的报告货币为326.602. 这些资产中的很大一部分，即 95.706 是现金和短期投资。与去年的数据相比，该部分的变化率为1.550%. 公司的长期投资虽然不是其重点，但以报告货币计算的5.237（如果有的话）为5.237。这表明与上一报告期相比，89.266% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 67.956. 这一数字表明，4.357% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 381.225. 这方面的年同比变化率为 -0.096%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为101.073，存货估值为 128.51，商誉估值为 0（如有. 无形资产总额（如果有）按 16.45 估值. 应付账款和短期债务分别为 60.91 和 45.71. 债务总额为113.66，债务净额为 17.96. 其他流动负债为 1.39，加上总负债 307.86. 最后，如果存在推荐股票，则其估值为 0.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

balance-sheet.row.cash-and-short-term-investments

208.6695.737.5136.3
17.2
17.5
10

balance-sheet.row.short-term-investments

0000
0
0
0

balance-sheet.row.net-receivables

279.04101.149.167.8
55.5
35.4
42.4

balance-sheet.row.inventory

564.08128.5145.1113
94.3
73.5
72.3

balance-sheet.row.other-current-assets

71.691.319.814.5
12.8
16.2
58.9

balance-sheet.row.total-current-assets

1123.47326.6251.6331.6
179.9
142.7
141.3

balance-sheet.row.property-plant-equipment-net

1190.14324.1297.3235.4
169.8
136.6
115.8

balance-sheet.row.goodwill

0000
0
0
0

balance-sheet.row.intangible-assets

63.716.515.914.3
12.6
12.3
10.9

balance-sheet.row.goodwill-and-intangible-assets

63.716.515.914.3
12.6
12.3
10.9

balance-sheet.row.long-term-investments

13.325.22.83.5
0.2
0.5
3.3

balance-sheet.row.tax-assets

42.6116.78.310.3
13.5
13.1
12.6

balance-sheet.row.other-non-current-assets

-25.920-8.3-10.3
-13.5
0
0

balance-sheet.row.total-non-current-assets

1283.86362.5315.9253.2
182.6
162.5
142.6

balance-sheet.row.other-assets

25.9208.310.3
13.5
0
0

balance-sheet.row.total-assets

2433.25689.1575.8595
376
305.1
283.8

balance-sheet.row.account-payables

160.6960.945.928.5
28.4
18.5
14.7

balance-sheet.row.short-term-debt

111.145.73.63.1
2
1.5
18.3

balance-sheet.row.tax-payables

17.529.34.97.6
13.8
8.2
2.3

balance-sheet.row.long-term-debt-total

97689.410.3
35.9
33.9
25

Deferred Revenue Non Current

47.2623.27.59.2
35
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

8.59---
-
-
-

balance-sheet.row.other-current-liab

237.31.450.175.5
73.5
1.4
28.7

balance-sheet.row.total-non-current-liabilities

160.46131.49.410.3
35.9
99.4
72.2

balance-sheet.row.other-liabilities

146.11048.659.6
60.6
0
0

balance-sheet.row.capital-lease-obligations

87.2523.321.218
12.4
10.4
0

balance-sheet.row.total-liab

818.72307.9154.1173.9
198.3
155.7
136.2

balance-sheet.row.preferred-stock

0000
5.6
2.7
0

balance-sheet.row.common-stock

1.210.30.30.3
33
33
50

balance-sheet.row.retained-earnings

775.36165.1214.1196
147.9
116.8
98.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

74.692317.713.2
-5.6
-2.7
0

balance-sheet.row.other-total-stockholders-equity

763.27192.7189.5211.6
-3.3
-0.4
-0.5

balance-sheet.row.total-stockholders-equity

1614.53381.2421.7421.2
177.7
149.4
147.7

balance-sheet.row.total-liabilities-and-stockholders-equity

2433.25689.1575.8595
376
305.1
283.8

balance-sheet.row.minority-interest

0000
0
0
0

balance-sheet.row.total-equity

1614.53381.2421.7421.2
177.7
149.4
147.7

balance-sheet.row.total-liabilities-and-total-equity

2433.25---
-
-
-

Total Investments

13.325.22.83.5
0.2
0.5
3.3

balance-sheet.row.total-debt

232.77113.721.218
37.4
35.4
43.3

balance-sheet.row.net-debt

24.1118-16.3-118.3
20.2
17.9
33.2

现金流量表

在 PolyPeptide Group AG 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.709 的转变。该公司最近通过发行 0 扩大了股本，与上一年相比出现了0.000 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 0. 公司的投资活动产生了现金使用净额，按报告货币计算达到-59512000.000. 与上一年相比， -0.241 发生了变化. 在同一时期，公司记录了 30.47, -2.78 和 -55.17，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 139.72，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln

USD
Growth
TTM202320222021202020192018

cash-flows.row.net-income

-43.67-51.47.847.3
31.3
25.7
23.8

cash-flows.row.depreciation-and-amortization

49.4730.52418.7
16.1
15.8
14.4

cash-flows.row.deferred-income-tax

46.423.113.228.7
0
0
0

cash-flows.row.stock-based-compensation

2.050.81.21.2
0
0
0

cash-flows.row.change-in-working-capital

-29.3446.2-14.3-29.9
-43.5
11.4
-15

cash-flows.row.account-receivables

-10.56018.8-12.2
-21.4
8.2
-10.7

cash-flows.row.inventory

-17.6215.5-33.1-17.7
-22.1
-1.2
2

cash-flows.row.account-payables

0000
0
-8.2
10.7

cash-flows.row.other-working-capital

-1.1630.700
0
12.6
-17

cash-flows.row.other-non-cash-items

63.457.3-26.3-8.6
45.6
2.6
-0.3

cash-flows.row.net-cash-provided-by-operating-activities

41.95000
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-128-56.7-75.1-74
-40.6
-19.7
-18.3

cash-flows.row.acquisitions-net

0000
0
4.4
0

cash-flows.row.purchases-of-investments

0000
0
2.2
-0.3

cash-flows.row.sales-maturities-of-investments

0000
0
3
0

cash-flows.row.other-investing-activites

-9.95-2.8-3.3-6.9
-1.9
-2.2
0

cash-flows.row.net-cash-used-for-investing-activites

-137.95-59.5-78.4-80.8
-42.6
-12.3
-18.6

cash-flows.row.debt-repayment

-3.51-55.2-3.3-41.4
-9.1
-8
-6.9

cash-flows.row.common-stock-issued

13.79017.2182.1
0
0
0

cash-flows.row.common-stock-repurchased

-13.930-13.9-5.5
0
-16.6
0

cash-flows.row.dividends-paid

-9.670-9.7-135.3
0
0
0

cash-flows.row.other-financing-activites

71.01139.7-17.2130.9
2.4
-11.3
3.5

cash-flows.row.net-cash-used-provided-by-financing-activities

57.6884.5-26.9130.9
-6.7
-35.9
-3.3

cash-flows.row.effect-of-forex-changes-on-cash

-2.27-3.31.111.7
-0.5
0.1
-0.1

cash-flows.row.net-change-in-cash

-40.658.2-98.8119.1
-0.3
7.5
0.9

cash-flows.row.cash-at-end-of-period

208.6695.737.5136.3
17.2
17.5
10

cash-flows.row.cash-at-beginning-of-period

249.2537.5136.317.2
17.5
10
9.1

cash-flows.row.operating-cash-flow

41.9536.55.557.4
49.5
55.6
22.9

cash-flows.row.capital-expenditure

-128-56.7-75.1-74
-40.6
-19.7
-18.3

cash-flows.row.free-cash-flow

-86.05-20.2-69.6-16.6
8.9
35.9
4.6

利润表行

PolyPeptide Group AG 的收入与上期相比变化了 0.140%。据报告, PPGN.SW 的毛利润为 4.64。该公司的营业费用为 41.11，与上年相比变化了 -2.910%. 折旧和摊销费用为 30.47，与上一会计期间相比变化了 0.484%. 营业费用报告为 41.11，显示-2.910% 的同比变化。 销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。 基于近期数据的EBITDA为 0，同比增长-3.911%. 营业收入为 -36.47，与上年相比变化了-3.911%. 净利润的变化率为 -7.623%。去年的净收入为-51.44.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

income-statement-row.row.total-revenue

601.35320.4281282.1
224.3
202.6
179.6

income-statement-row.row.cost-of-revenue

544.59315.7229182.4
151.1
131
117.5

income-statement-row.row.gross-profit

56.764.65299.7
73.2
71.6
62.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0

income-statement-row.row.research-development

2.71---
-
-
-

income-statement-row.row.selling-general-administrative

70.54---
-
-
-

income-statement-row.row.selling-and-marketing-expenses

8.96---
-
-
-

income-statement-row.row.other-expenses

0000
0
13.3
12.1

income-statement-row.row.operating-expenses

99.7941.142.337
32.3
38
34.4

income-statement-row.row.cost-and-expenses

644.37356.8271.3219.5
183.4
169.1
151.8

income-statement-row.row.interest-income

8.770.12.12.8
3.2
0.1
0.1

income-statement-row.row.interest-expense

05.62.12.8
3.3
3.2
4.1

income-statement-row.row.selling-and-marketing-expenses

8.96---
-
-
-

income-statement-row.row.total-other-income-expensenet

-29.37-21.8-5-7.6
-6.6
-3.3
1.7

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
13.3
12.1

income-statement-row.row.total-operating-expenses

-29.37-21.8-5-7.6
-6.6
-3.3
1.7

income-statement-row.row.interest-expense

05.62.12.8
3.3
3.2
4.1

income-statement-row.row.depreciation-and-amortization

42.0530.520.516.1
14.1
15.9
14.4

income-statement-row.row.ebitda-caps

20.74---
-
-
-

income-statement-row.row.operating-income

-21.3-36.512.567.4
44.3
33.5
27.8

income-statement-row.row.income-before-tax

-50.68-58.27.659.8
37.7
30.2
29.5

income-statement-row.row.income-tax-expense

12.19-6.80.212.6
6.3
4.5
5.6

income-statement-row.row.net-income

-43.67-51.47.847.3
31.3
25.7
23.8
类似股票
您可能还对以下内容感兴趣：
CHSYF
China Medical System Holdings Limited.
0.9313 USD
PNK
600479.SS
ZhuZhou QianJin Pharmaceutical Co.,Ltd.
10.92 CNY
SHH
WOCKPHARMA.BO
Wockhardt Limited.
532.5 INR
BSE
185750.KS
Chong Kun Dang Pharmaceutical Corp..
100300 KRW
KSC
ERIS.NS
Eris Lifesciences Limited.
848.1 INR
NSE
300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd..
22.39 CNY
SHZ
TKPHF
Takeda Pharmaceutical Company Limited.
26.83 USD
PNK
MVP.AX
Medical Developments International Limited.
0.61 AUD
ASX
APLLTD.NS
Alembic Pharmaceuticals Limited.
1001.35 INR
NSE
128940.KS
Hanmi Pharm. Co., Ltd..
321500 KRW
KSC
002390.KS
HANDOK Inc..
13700 KRW
KSC

常见问题

什么是 PolyPeptide Group AG (PPGN.SW) 总资产是多少？

PolyPeptide Group AG (PPGN.SW) 总资产为 689088000.000.

什么是企业年收入？

年收入为 320372000.000.

企业利润率是多少？

公司利润率为 0.015.

什么是公司自由现金流？

自由现金流为 -0.498.

什么是企业净利润率？

净利润率为 -0.161.

企业总收入是多少？

总收入为 -0.106.

什么是 PolyPeptide Group AG (PPGN.SW) 净利润？{{符号}}净利润（净收入）是多少？

净利润（净收入）为 -51440000.000.

公司总债务是多少？

债务总额为 113662000.000.

营业费用是多少？

运营支出为 41110000.000.

公司现金是多少？

企业现金为 95706000.000.